Bedford Laboratories launches Dactinomycin for Injection
Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 ...
Read more...
Wisdom and Dignity from a 21-Year-Old Cancer Patient
Amersfoort, The Netherlands (Vocus) July 26, 2010 -- A cancer diagnosis is devastating news no matter what the circumstance. But at age 21, the majority of young men are coping with final exams and...
Read more...
The Collapse of Cancer Metastases Hypothesis PRW -- The Announcement of New Study Results, Sergey N. Rumyantsev, Andent Inc.
Jersey City, NJ (PRWEB) April 15, 2010 -- The announcement of new study results -- Sergey N. Rumyantsev Director of research, Andent Inc. For the last 50 years the prevailing paradigm in cancer...
Read more...
"Being a Proper Man is About Having a 'tache" Says Keith Lemon
Read more...
The Approach to the Patient With Synchronous Bilateral Germ Cell Tumors: A ... - Cancer Network
Read more...
|